FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products

Comparative analytical, nonclinical, and clinical studies are necessary to protect patient safety
  • Recommend
  • Tweet
  • Print
  • Email

Additional Resources

In this presentation, BIO urges the Food and Drug Administration to prioritize patient safety and incentives for innovation at a public hearing on biosimilars.

Hide Date: